GSK sells Chinese Tykerb rights to Eddingpharm; Novartis cuts 120 jobs in Fort Worth;

@FiercePharma: Trending yesterday: U.S. adults still skipping pills to save money, CDC finds. Article | Follow @FiercePharma

@EricPFierce: Drugmakers with plants in EU still sweating whether China, India will meet deadline for new API regulations. Report | Follow @EricPFierce

> GlaxoSmithKline ($GSK) licensed the Chinese rights to its breast cancer treatment Tykerb to Eddingpharm, which will import and sell the drug in the country. Report

> Novartis ($NVS) laid off 120 Alcon employees in Fort Worth, TX, with plans to move the jobs to Cambridge, MA; the Texas employees can apply for jobs in Cambridge or elsewhere within Alcon. Report

> Apotex did not initially warn women of packaging problems with its Alysena birth controll pill but issued a retailer-level recall; Health Canada upgraded the recall this week to require that patients be notified. Report

> GW Pharmaceuticals said its cannabis-based medicine Sativex was moved to a less-restrictive category on the U.K. drug schedule. Report

> General Electric ($GE) and iBio ($IBIO) won a contract to design a vaccine-manufacturing plant in Brazil. Report

Medical Device News

@FierceMedDev: Report: Device tax is hard to decipher and kills jobs. More | Follow @FierceMedDev

@MarkHFierce: Med device VC continues to be steady for late stage companies. iRhythm pulled in a $16M Series D. Release | Follow @MarkHFierce

 @DamianFierce: St. Jude won EU approval to treat dystonia with its deep-brain simulators. News | Follow @DamianFierce

> Abbott/BG heart failure Dx gains CE mark. More

> Smiths Medical faces FDA Class I recall over sleep alarm cables. Item

> Covidien plans to slash 183 jobs in NY plant closure. Report

Biotech News

@FierceBiotech: Trending: Groton throws up a new hurdle to Pfizer's R&D demolition plan. Story | Follow @FierceBiotech

@JohnCFierce: Fun list from Evaluate on the top 10 blockbuster busts in biopharma. List | Follow @JohnCFierce.

@RyanMFierce: Started my day 2 here at BioIT13 with a story about Novartis' big decision on whether to buy Proteon in $550M deal. News | Follow @RyanMFierce

> VistaGen raises $36M for stem cell tech. More

> Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit primary PhII goal. Article

> FDA stokes blockbuster hopes with 'breakthrough' brand for Pfizer cancer drug. News

Drug Delivery News

@MichaelGFierce: From SpringLeaf's ashes, scPharma continues with minipump delivery. Article | Follow @MichaelGFierce

> TissueGen launches Elute drug-delivering fiber. News

> 3-D printer makes synthetic tissue for drug delivery. Report

> Self-assembling cancer drugs deliver themselves. Item

> Ambrx's cancer antibody delivery tech wins Astellas partnership. More

> Nano-delivered cell gatekeepers can improve drug performance, study finds. Story

And Finally... Scientists are making progress toward an "artificial pancreas" for diabetics. Report